AVBP

ArriVent BioPharma, Inc.

Price Chart

Latest Quote

$31.17

+0.84 (+2.77%)

Current Price

Previous Close	$30.33
Open	$30.63
Day High	$31.70
Day Low	$30.27
Volume	185,431

Fetched: 2026-06-17T16:30:29

Stock Information

Shares Outstanding	46.57M
Total Debt	$419K
Cash Equivalents	$326.38M
Net Income	$-145.24M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.45B
EPS (TTM)	$-3.38
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.09B
Income	$-145.24M
Book/sh	$7.15
Cash/sh	$7.01
Employees	77

Financial Ratios

Quick Ratio	13.06
Current Ratio	13.95
Debt/Eq	0.13

Returns & Margins

ROA	-34.72%
ROE	-55.17%

Ownership

Insider Ownership	1.63%
Institutional Ownership	95.81%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-8.91
P/B	4.36

Analyst Data

Recommendation	strong_buy
Target Price	$43.64

Technical Indicators

SMA20	$29.57
SMA50	$29.27
SMA200	$23.33
RSI	66.59
ATR	1.9469

Shares Float	29.78M
Short Float	17.62%
Short Ratio	18.34
Volatility	1.42
Rel Volume	0.33

Performance History

Week	+2.23%
Month	+15.27%
Quarter	+36.65%
6 Months	+31.85%
YTD	+49.86%
Year	+22.62%
10 Years	+55.85%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$31.17	185,431
2026-06-16	$30.33	429,900
2026-06-15	$30.30	352,600
2026-06-12	$30.54	448,200
2026-06-11	$30.20	432,600
2026-06-10	$30.49	373,800
2026-06-09	$30.55	360,200
2026-06-08	$30.50	438,200
2026-06-05	$30.35	634,900
2026-06-04	$33.09	744,700
2026-06-03	$29.78	712,200
2026-06-02	$29.92	911,700
2026-06-01	$30.68	1,253,700
2026-05-29	$30.27	1,309,800
2026-05-28	$26.97	408,700
2026-05-27	$27.47	433,600
2026-05-26	$27.94	552,300
2026-05-22	$26.73	433,400
2026-05-21	$27.00	475,400
2026-05-20	$27.22	454,400
2026-05-19	$26.15	435,400
2026-05-18	$27.04	367,400

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

📰 Latest News

A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate

Simply Wall St. • 2026-05-10T06:08:32Z

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Zacks • 2026-04-15T16:00:01Z

Are Medical Stocks Lagging AstraZeneca (AZN) This Year?

Zacks • 2026-04-13T13:40:04Z

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Zacks • 2026-04-06T13:55:02Z

Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest

Simply Wall St. • 2026-04-05T01:12:36Z

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

Zacks • 2026-03-26T13:40:02Z

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?

Zacks • 2026-03-10T13:55:02Z

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

Zacks • 2026-03-10T13:40:02Z

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More

24/7 Wall St. • 2025-12-23T13:13:04Z

We Think ArriVent BioPharma (NASDAQ:AVBP) Needs To Drive Business Growth Carefully

Simply Wall St. • 2025-11-12T10:34:16Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$177,534,000	$94,308,000	$74,590,000	$36,906,000
Net Non Operating Interest Income Expense	$11,226,000	$13,820,000	$5,257,000	$0
Operating Expense	$177,534,000	$94,308,000	$74,590,000	$36,906,000
General And Administrative Expense	$24,183,000	$15,304,000	$9,706,000	$6,473,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Net Interest Income	$11,226,000	$13,820,000	$5,257,000	$0
Interest Income	$11,226,000	$13,820,000	$5,257,000	$0
Normalized Income	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Net Income From Continuing And Discontinued Operation	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Total Operating Income As Reported	$-177,534,000	$-94,308,000	$-74,590,000	$-36,906,000
Net Income Common Stockholders	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Net Income	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Net Income Including Noncontrolling Interests	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Net Income Continuous Operations	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Pretax Income	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Interest Income Non Operating	$11,226,000	$13,820,000	$5,257,000	$0
Operating Income	$-177,534,000	$-94,308,000	$-74,590,000	$-36,906,000
Per Share
Diluted EPS	$-4.32	$-2.56	$-2.17	$-1.15
Basic EPS	$-4.32	$-2.56	$-2.17	$-1.15
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-177,534,000	$-94,308,000	$-74,590,000	$-36,906,000
EBITDA (Bullshit earnings)	$-177,534,000	$-94,308,000	$-74,590,000	$-36,906,000
EBIT	$-177,534,000	$-94,308,000	$-74,590,000	$-36,906,000
Diluted Average Shares	$38,462,600	$31,469,328	$31,956,657	$31,956,657
Basic Average Shares	$38,462,600	$31,469,328	$31,956,657	$31,956,657
Diluted NI Availto Com Stockholders	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Research And Development	$153,351,000	$79,004,000	$64,884,000	$30,433,000
Selling General And Administration	$24,183,000	$15,304,000	$9,706,000	$6,473,000
Other Gand A	$24,183,000	$15,304,000	$9,706,000	$6,473,000

Fetched: 2026-06-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$307,224,000	$257,654,000	$-153,193,000	$-85,109,000
Total Assets	$333,169,000	$274,942,000	$163,098,000	$182,833,000
Total Non Current Assets	$272,000	$47,963,000	$3,130,000	$211,000
Other Non Current Assets	$190,000	$126,000	$107,000	$72,000
Non Current Deferred Assets	$69,000	$0	$2,732,000	$0
Current Assets	$332,897,000	$226,979,000	$159,968,000	$182,622,000
Other Current Assets	$19,830,000	$7,209,000	$8,450,000	$18,417,000
Prepaid Assets	$186,000	$407,000	$368,000	$333,000
Receivables	$60,000	$500,000	$761,000	$500,000
Other Receivables	$60,000	-	$240,000	$177,000
Taxes Receivable	$0	$500,000	$761,000	$500,000
Cash Cash Equivalents And Short Term Investments	$312,821,000	$218,863,000	$150,389,000	$163,372,000
Cash And Cash Equivalents	$45,540,000	$74,293,000	$150,389,000	$163,372,000
Cash Financial	-	-	-	$163,372,000
Debt
Total Debt	$14,000	$176,000	$317,000	$139,000
Long Term Debt And Capital Lease Obligation	$0	$14,000	$177,000	$11,000
Current Debt And Capital Lease Obligation	$14,000	$162,000	$140,000	$128,000
Liabilities
Total Liabilities Net Minority Interest	$25,945,000	$17,288,000	$316,291,000	$267,942,000
Total Non Current Liabilities Net Minority Interest	$0	$14,000	$304,667,000	$259,582,000
Current Liabilities	$25,945,000	$17,274,000	$11,624,000	$8,360,000
Payables And Accrued Expenses	$19,386,000	$12,949,000	$8,131,000	$5,555,000
Payables	$5,934,000	$3,782,000	$4,532,000	$3,094,000
Accounts Payable	$5,934,000	$3,782,000	$4,532,000	$3,094,000
Equity
Common Stock Equity	$307,224,000	$257,654,000	$-153,193,000	$-85,109,000
Total Equity Gross Minority Interest	$307,224,000	$257,654,000	$-153,193,000	$-85,109,000
Stockholders Equity	$307,224,000	$257,654,000	$-153,193,000	$-85,109,000
Gains Losses Not Affecting Retained Earnings	$14,000	$-211,000	$0	-
Other Equity Adjustments	$14,000	$-211,000	-	-
Retained Earnings	$-404,641,000	$-238,333,000	$-157,845,000	$-88,512,000
Preferred Securities Outside Stock Equity	-	$0	$304,490,000	$259,571,000
Preferred Stock Equity	-	-	-	-
Other Equity Interest	-	-	-	-
Other
Ordinary Shares Number	$42,452,251	$33,706,765	$31,956,657	$31,956,657
Share Issued	$42,452,251	$33,706,765	$31,956,657	$31,956,657
Tangible Book Value	$307,224,000	$257,654,000	$-153,193,000	$-85,109,000
Invested Capital	$307,224,000	$257,654,000	$-153,193,000	$-85,109,000
Working Capital	$306,952,000	$209,705,000	$148,344,000	$174,262,000
Capital Lease Obligations	$14,000	$176,000	$317,000	$139,000
Total Capitalization	$307,224,000	$257,654,000	$-153,193,000	$-85,109,000
Additional Paid In Capital	$711,847,000	$496,195,000	$4,652,000	$3,403,000
Capital Stock	$4,000	$3,000	$0	$0
Common Stock	$4,000	$3,000	$0	$0
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$0	$14,000	$177,000	$11,000
Current Capital Lease Obligation	$14,000	$162,000	$140,000	$128,000
Pensionand Other Post Retirement Benefit Plans Current	$6,545,000	$4,163,000	$3,353,000	$2,677,000
Current Accrued Expenses	$13,452,000	$9,167,000	$3,599,000	$2,461,000
Investments And Advances	$0	$47,683,000	$0	-
Net PPE	$13,000	$154,000	$291,000	$139,000
Gross PPE	$13,000	$154,000	$291,000	$139,000
Buildings And Improvements	$13,000	$154,000	$291,000	$139,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$267,281,000	$144,570,000	$0	-

Fetched: 2026-06-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-160,588,000	$-70,212,000	$-55,842,000	$-43,631,000
Operating Activities
Operating Cash Flow	$-160,588,000	$-70,212,000	$-55,842,000	$-43,631,000
Cash Flow From Continuing Operating Activities	$-160,588,000	$-70,212,000	$-55,842,000	$-43,631,000
Investing Activities
Investing Cash Flow	$-71,228,000	$-192,465,000	$0	$0
Cash Flow From Continuing Investing Activities	$-71,228,000	$-192,465,000	$0	$0
Financing Activities
Issuance Of Capital Stock	$202,631,000	$185,950,000	$44,919,000	$169,708,000
Financing Cash Flow	$203,063,000	$186,581,000	$42,859,000	$169,723,000
Cash Flow From Continuing Financing Activities	$203,063,000	$186,581,000	$42,859,000	$169,723,000
Net Other Financing Charges	$-70,000	-	$-2,414,000	-
Net Common Stock Issuance	$202,631,000	$185,950,000	$0	$2,000
Common Stock Issuance	$202,631,000	$185,950,000	$0	$2,000
Net Preferred Stock Issuance	-	$0	$44,919,000	$169,706,000
Preferred Stock Issuance	-	$0	$44,919,000	$169,706,000
Other
End Cash Position	$45,540,000	$74,293,000	$150,389,000	$163,372,000
Beginning Cash Position	$74,293,000	$150,389,000	$163,372,000	$37,280,000
Changes In Cash	$-28,753,000	$-76,096,000	$-12,983,000	$126,092,000
Proceeds From Stock Option Exercised	$502,000	$631,000	$354,000	$15,000
Net Investment Purchase And Sale	$-71,228,000	$-192,465,000	$0	$0
Sale Of Investment	$201,706,000	$1,699,000	$25,000,000	$0
Purchase Of Investment	$-272,934,000	$-194,164,000	$-25,000,000	$0
Change In Working Capital	$-3,774,000	$7,068,000	$12,596,000	$-7,149,000
Change In Other Current Liabilities	$-21,000	$-2,000	$25,000	$0
Change In Other Current Assets	$0	$-20,000	$-35,000	$16,000
Change In Payables And Accrued Expense	$8,808,000	$5,626,000	$2,935,000	$6,413,000
Change In Accrued Expense	$6,667,000	$6,377,000	$1,556,000	$3,613,000
Change In Payable	$2,141,000	$-751,000	$1,379,000	$2,800,000
Change In Account Payable	$2,141,000	$-751,000	$1,379,000	$2,800,000
Change In Prepaid Assets	$-12,561,000	$1,464,000	$9,671,000	$-13,578,000
Other Non Cash Items	$-3,026,000	-	-	-
Stock Based Compensation	$12,520,000	$3,208,000	$895,000	$424,000
Net Income From Continuing Operations	$-166,308,000	$-80,488,000	$-69,333,000	$-36,906,000
Repayment Of Debt	-	-	-	$0
Issuance Of Debt	-	-	-	$0
Net Issuance Payments Of Debt	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$0
Long Term Debt Payments	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0
Net Intangibles Purchase And Sale	-	-	-	$0
Purchase Of Intangibles	-	-	-	$0

Fetched: 2026-06-15